Skip to content
FEROCE

GLP-1 follow-up between visits.

Patients on GLP-1 therapy go through dose increases, side effects and refills between visits that are often weeks apart. A weekly check-in shows your team how each patient is doing and who may be at risk of stopping.

See how it works

Why the weeks between visits matter

In a 2025 JAMA Network Open study of 125,474 adults who started a GLP-1 medication, 46.5% of patients with type 2 diabetes and 64.8% of patients without diabetes stopped within one year. Moderate or severe gastrointestinal side effects were associated with a higher rate of stopping.

What patients answer each week

  • Whether they took their dose, took it late or missed it, and why
  • Their weight that morning
  • Nausea and other digestive side effects, with severity
  • Protein and activity goals from their care plan
  • Refills and upcoming labs

What your physicians see

A weight trend since the start of treatment, with clinic measurements marked separately from home weights. Twelve weeks of dose history. Side effects by week. One status per patient: on track, needs review, or awaiting reply.

Sources
How it works

One loop, every week, for every patient.

  1. 01

    Patients check in

    An automated text in your clinic’s name opens a two-minute check-in. One tap per question.

    Your weekly check-in is ready. It takes 2 minutes. Open my check-in
    Any nausea this week?
    NoneMildModerateSevere
  2. 02

    Answers become structured data

    Each answer is stored as patient-reported information, week after week, in one longitudinal record.

    • Dose this weekTaken
    • Home weight196.4 lb
    • NauseaMild
    • Protein goal5 of 7 days
  3. 03

    Physicians see the whole panel

    One dashboard shows who is on track and who missed doses or reported side effects, before the next visit.

    • Sarah MitchellOn track
    • Marcus ReedNeeds review
    • Linda ParkNeeds review
    • Priya RamanAwaiting reply

Protocols written by physicians and approved by your medical director.

What your physicians see.

Pick a patient. Demo data, all patients are fictional.

Try a situation
app.feroceai.com/patients/marcus
Northside Primary CareDemo data
MR
Marcus ReedNeeds review
Tirzepatide 7.5 mg weekly · Week 24 · Next visit Nov 11
Weight
240.8 lb
This week
Since start
−16 lb
from 256.8 lb
Doses on schedule
10 of 12
Last 12 weeks
Side effects
Constipation, moderate
This week
For review before the next visit: Missed dose and a new side effect reported this week.
Weight since start of treatment
Home weightClinic visit
238249259W0W5W10W15W20W24
Weekly doses Patient-reported
12 weeks agoThis week
9:41
Northside Primary Care
Your weekly check-in
2 minutes · one tap per question · Marcus
Did you take your dose this week?
YesLateNo
Your weight this morning
240.8 lb
Any other side effect?
NoneConstipationHeartburnOther
Days you reached your protein goal
0–23–45–7
Sent to your care team
AA feroceai.com

This week, on Marcus’s phone.

Questions

No. Dosing decisions stay with your clinicians. The check-in reports what the patient took and how they feel.

The check-in is medication-agnostic. It follows the dose and schedule your clinic prescribed, for example weekly semaglutide or tirzepatide.

The patient is told right away to call your clinic, or 911 in an emergency, and the answer appears on your dashboard.

See your patients’ weeks, not just their visits.

A 30-minute walkthrough of the patient check-in and the physician dashboard, with demo patients.

We reply within one business day.